{"id":"fh-006-shr-1316-bp102","safety":{"commonSideEffects":[{"rate":null,"effect":"unknown"}]},"_chembl":{"chemblId":"CHEMBL4297828","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"FH-006 works by binding to the molecular target, which results in the desired therapeutic effect.","oneSentence":"FH-006 is a small molecule drug that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:54:03.892Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"unknown"}]},"trialDetails":[{"nctId":"NCT07241767","phase":"PHASE2","title":"A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-11-12","conditions":"Lung Cancer","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"FH-006 ; SHR-1316 ; BP102","genericName":"FH-006 ; SHR-1316 ; BP102","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FH-006 is a small molecule drug that targets the molecular target. Used for unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}